Mangalam Drugs And Organics Ltd vs Medicamen Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Mangalam Drugs and Organics Ltd is ₹ 30.38 as of 18 May 15:30 . The P/E Ratio of Mangalam Drugs and Organics Ltd changed from 17.5 on March 2025 to 17.5 on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Medicamen Biotech Ltd changed from 53.8 on March 2021 to 86.2 on March 2025 . This represents a CAGR of 9.89% over 5 years The Market Cap of Mangalam Drugs and Organics Ltd changed from ₹ 146.65 crore on March 2024 to ₹ 117.48 crore on March 2025 . This represents a CAGR of -10.50% over 2 yearsThe Market Cap of Medicamen Biotech Ltd changed from ₹ 652.37 crore on March 2021 to ₹ 612.46 crore on March 2025 . This represents a CAGR of -1.25% over 5 years The revenue of Mangalam Drugs and Organics Ltd for the Mar '26 is ₹ 67.38 crore as compare to the Dec '25 revenue of ₹ 58.6 crore. This represent the growth of 14.98% The revenue of Medicamen Biotech Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 47.44 crore. This represent the decline of -100% The ebitda of Mangalam Drugs and Organics Ltd for the Mar '26 is ₹ -5.53 crore as compare to the Dec '25 ebitda of ₹ -1.32 crore. This represent the growth of 318.94% The ebitda of Medicamen Biotech Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 4.91 crore. This represent the decline of -100% The net profit of Mangalam Drugs and Organics Ltd changed from ₹ 2.68 crore to ₹ -13.42 crore over 8 quarters. This represents a CAGR of NaN% The net profit of Medicamen Biotech Ltd changed from ₹ 0.8 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Mangalam Drugs and Organics Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Medicamen Biotech Ltd changed from 9.78 % on March 2021 to 13.45 % on March 2025 . This represents a CAGR of 6.58% over 5 years .

About Mangalam Drugs and Organics Ltd

Mangalam Drugs and Organics Limited was initially incorporated as 'Advent Pharma Private Limited' on April 18, 1972.
On July 1, 1997, the Company changed the name from Advent Pharma Private Limited to Mangalam Drugs and Organics Private Limited.
Thereafter, it converted the status into a Public Limited Company, changing the name to Mangalam Drugs and Organics Limited on August 10, 2001.
The company was established to set up a plant for manufacture of organic and inorganic chemicals. The company is engaged in the manufacturing of chemicals, such as active pharma ingredients (API) perfumery, disperse dye intermediates, bulk drugs and bulk drugs intermediates.
The company has their manufacturing facilities at Vapi in Gujarat and Sangamner in Maharashtra.

About Medicamen Biotech Ltd

A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets.
The Company has presence over 35+ countries.
Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market.
MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan).
The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

FAQs for the comparison of Mangalam Drugs and Organics Ltd and Medicamen Biotech Ltd

Which company has a larger market capitalization, Mangalam Drugs and Organics Ltd or Medicamen Biotech Ltd?

Market cap of Mangalam Drugs and Organics Ltd is 47 Cr while Market cap of Medicamen Biotech Ltd is 379 Cr

What are the key factors driving the stock performance of Mangalam Drugs and Organics Ltd and Medicamen Biotech Ltd?

The stock performance of Mangalam Drugs and Organics Ltd and Medicamen Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Mangalam Drugs and Organics Ltd and Medicamen Biotech Ltd?

As of May 18, 2026, the Mangalam Drugs and Organics Ltd stock price is INR ₹30.01. On the other hand, Medicamen Biotech Ltd stock price is INR ₹280.15.

How do dividend payouts of Mangalam Drugs and Organics Ltd and Medicamen Biotech Ltd compare?

To compare the dividend payouts of Mangalam Drugs and Organics Ltd and Medicamen Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.